(Total Views: 244)
Posted On: 01/03/2018 1:23:28 PM
Post# of 72446
Nice summary from BioHedge at other board:
I think some on the board are missing the boat on this. The fact that B was able to stop some patients from getting OM and delaying those that did by 10-14 days... is a HUGE win. The administration was nothing more than a swish and spit. Imagine the results once the product is compounded to coat the mucosal lining and stay there for any prolonged amount of time.
Brilacidin is a significant drug. Just look at the multiple indications it is working on (OM, UC, ABSSSI). It has not failed one trial. Add to that K and P and we have a significant opportunity. Once Leo gets 3rd party verification, with capital to work with the narrative changes. I don't care if it's a 5M or 30M upfront deal, I just want the validation and some relief to the Balance Sheet.
I think some on the board are missing the boat on this. The fact that B was able to stop some patients from getting OM and delaying those that did by 10-14 days... is a HUGE win. The administration was nothing more than a swish and spit. Imagine the results once the product is compounded to coat the mucosal lining and stay there for any prolonged amount of time.
Brilacidin is a significant drug. Just look at the multiple indications it is working on (OM, UC, ABSSSI). It has not failed one trial. Add to that K and P and we have a significant opportunity. Once Leo gets 3rd party verification, with capital to work with the narrative changes. I don't care if it's a 5M or 30M upfront deal, I just want the validation and some relief to the Balance Sheet.
(3)
(0)
